| 货号 | 14278-100mg |
| 描述 | Prasugrel is a thienopyridine prodrug that is converted by esterases to a receptor antagonist for purinergic P2Y12 receptors.1 The blockade of P2Y12 receptor activation prevents platelet aggregation.2,3 Prasugrel is metabolized by the liver- and intestinal-dominant carboxylesterases CE1 and CE2 to give a mixture of four enantiomers that inhibit platelet aggregation.4,5 |
| 别名 | CS 747;Effient;LY640315; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Michelson, A.D. Advances in antiplatelet therapy. Hematology Am.Soc.Hematol.Educ.Program 2011, 62-69 (2011). 2.Sugidachi, A.,Asai, F.,Ogawa, T., et al. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. British Journal of Pharmacology 129(7), 1439-1446 (2000). 3.John, J. and Kosby, S.K.G. Current oral antiplatelets: Focus update on prasugrel. J.Am.Board Fam.Med. 25(3), 343-349 (2012). 4.Williams, E.T.,Jones, K.O.,Ponsler, G.D., et al. The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2. Drug Metabolism and Disposition 36(7), 1227-1232 (2008). 5.Sugidachi, A.,Asai, F.,Yoneda, K., et al. Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type Gi-linked P2T antagonist, CS-747. British Journal of Pharmacology 132(1), 47-54 (2001). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 373.4 |
| 分子式 | C20H20FNO3S |
| CAS号 | 150322-43-3 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |